Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2025 08:05 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq Global Market: NTHI), a clinical-stage medical biotechnology company, today announced a...
March 25, 2025 16:30 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (“NeOnc” or the “Company,” to be listed on the NASDAQ Global Market under the symbol: NTHI), a...
March 25, 2025 09:00 ET | Source: NeOnc Technologies Holdings, Inc.

NEONC Technologies Holdings, Inc. Appoints Dr. Alan Chiang to its Board of Directors

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical...
March 25, 2025 08:45 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical...
March 25, 2025 08:30 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical...
March 25, 2025 08:15 ET | Source: NeOnc Technologies Holdings, Inc.

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical...
March 25, 2025 08:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. Appoints Dr. Victoria Medvec to Board of Directors

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol NTHI), a clinical-stage medical...
October 07, 2024 11:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Receives Pharma Tech Outlook’s Top Drug Delivery Platform Award for 2024

WESTLAKE VILLAGE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has been recognized by Pharma Tech Outlook as the Top...
August 05, 2024 11:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

NeOnc’s second concurrent Phase 2 clinical study seeks further safety and preliminary evidence of biological effects of its lead drug candidate, NEO100™, on certain cancers of the brain and central...
July 24, 2024 11:15 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain Tumors

NEO212™ completes initial two cohorts of Phase 1 study under FDA Investigative New Drug (IND).Study tests the safety of NeOnc’s patented novel drug, NEO212™, which is the bioconjugation of its leading...